Bedell Frazier Investment Counselling’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bedell Frazier Investment Counselling’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-66,009	Closed	-$6.12M	–	109
2024 Q2	$6.12M	Sell	66,009 -5,257	-7%	-$471K	1.48%	23
2024 Q1	$6.76M	Sell	71,266 -203	-0.3%	-$18.8K	1.69%	21
2023 Q4	$6.38M	Sell	71,469 -4,846	-6%	-$360K	1.76%	20
2023 Q3	$5.57M	Buy	+76,315	New	+$6.1M	1.67%	24

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Bedell Frazier Investment Counselling's XBI Position: Q3 2024 in Review

Bedell Frazier Investment Counselling sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2024, closing a stake of 66,009 shares — an estimated $6.12M sold.

Bedell Frazier Investment Counselling first reported a position in XBI in Q3 2023 and held it in 4 quarters. The position peaked at $6.76M in Q1 2024. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

Bedell Frazier Investment Counselling reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2024 after selling out during the quarter.
Bedell Frazier Investment Counselling sold 66,009 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $6.12M.
Bedell Frazier Investment Counselling first reported a position in State Street SPDR S&P Biotech ETF in Q3 2023 and held it in 4 quarters.
Bedell Frazier Investment Counselling's State Street SPDR S&P Biotech ETF position peaked at $6.76M in Q1 2024.
769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Bedell Frazier Investment Counselling's 13F filing for Q3 2024, filed 13 Nov 2024.